Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
RegenXBio (RGNX) Stock Price & Analysis
512 Followers
RGNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.98 - $28.80
Previous Close$11.07
Volume507.89K
Average Volume (3M)518.90K
Market Cap
$545.26M
Enterprise Value$359.30M
Total Cash (Recent Filing)$275.26M
Total Debt (Recent Filing)$89.29M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 07, 2024EPS Estimate
-$1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.88
Shares Outstanding49,255,966
10 Day Avg. Volume901,320
30 Day Avg. Volume518,897
Standard Deviation0.17
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.90
Price to Sales (P/S)26.65
Price to Cash Flow (P/CF)-3.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.98
Enterprise Value/Gross Profit6.78
Enterprise Value/Ebitda-1.49
Forecast
1Y Price Target
$39.44Price Target Upside266.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
RegenXBio News
PremiumCompany Announcements
RegenXBio Announces Leadership Shuffle and Financial Outlook
Bulls Say, Bears Say
Bulls Say
Financial PerformanceREGENXBIO reported lower than expected net loss and is on track for RGX-121 BLA filing under the accelerated approval pathway for potential one-time gene therapy.
Pipeline ProgressInitial biomarker data from the AFFINITY DUCHENNE trial for RGX-202 shows well-tolerance and encouraging increases in microdystrophin expression.
Regulatory ApprovalThe imminent filing and anticipated approval of RGX-121 for MPS II (Hunter syndrome) provide near-term regulatory catalysts and a commercial product with a small but well-identified opportunity.
Bears Say
Competitive LandscapeGrowing competitive wAMD landscape with recent entrants showing extended duration and meaningful reductions in injection burden.
Dose ResponseThere is a lack of dose response making it unclear what dose might be brought forward.
EfficacyThe update raised questions around the cohort 6 efficacy results which were not provided separately despite the additional anti-VEGF run-in injections given to these patients.
---
Ownership Overview
8.33% Insiders
21.17% Mutual Funds
52.23% Other Institutional Investors
18.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $10.98 and its highest was $28.80 in the past 12 months.
What is RegenXBio’s market cap?
Currently, no data Available
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Aug 07, 2024 which is in 35 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on May 08, 2024. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$1.259 by -$0.121.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -$1.29.
How many shares outstanding does RegenXBio have?
RegenXBio has 49,255,966 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -$1.38 in its last earnings report, missing expectations of -$1.259. Following the earnings report the stock price went down -5.939%.
Which hedge fund is a major shareholder of RegenXBio?
Among the largest hedge funds holding RegenXBio’s share is Woodline Partners LP. It holds RegenXBio’s shares valued at 3M.
---
RegenXBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.44 (266.88% Upside)
$39.44 (266.88% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 96.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.5%
Last 30 Days ▲ 23.7%
Last 30 Days ▲ 23.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.62%
12-Months-Change
Fundamentals
Return on Equity
-60.80%
Trailing 12-Months
Asset Growth
-15.86%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
---
RGNX Earnings Call
Q1 2024
0:00 / 0:00
---
RGNX Stock 12 Month Forecast
Average Price Target
$39.44
▲(266.88% Upside)
Technical Analysis
Best Analysts Covering RGNX
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
-11.15%
reiterated a buy rating 2 months ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -11.15% per trade.
---